Free tool
FAERS Monitor: Idhifa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209606 or its brand name (Idhifa, Enasidenib Mesylate). Reports on generic versions are filed under their own applications.
Reports
3,369
Serious
2,076
62% of reports
Hospitalization
864
Death reported
839
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death682
- off label use246
- fatigue224
- nausea197
- hospitalisation186
- diarrhoea142
- platelet count decreased133
- decreased appetite121
- acute myeloid leukaemia119
- drug ineffective102
- asthenia92
- full blood count decreased81
- white blood cell count decreased76
- pyrexia74
- pneumonia68
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 90 |
| 2018 | 400 |
| 2019 | 424 |
| 2020 | 548 |
| 2021 | 395 |
| 2022 | 317 |
| 2023 | 372 |
| 2024 | 377 |
| 2025 | 276 |
| 2026 | 170 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute myeloid leukaemiaSignal | 119 | 48.0 | 40.2 | 5,395 |
| full blood count decreasedSignal | 81 | 25.2 | 20.3 | 1,852 |
| platelet count decreasedSignal | 133 | 7.8 | 6.6 | 785 |
| hospitalisationSignal | 186 | 7.6 | 6.6 | 1,060 |
| deathSignal | 682 | 4.9 | 4.6 | 2,232 |
| white blood cell count decreasedSignal | 76 | 4.4 | 3.5 | 196 |
| decreased appetiteSignal | 121 | 3.3 | 2.7 | 189 |
| fatigue | 224 | 1.8 | 1.6 | 81 |
| off label use | 246 | 1.8 | 1.6 | 82 |
| nausea | 197 | 1.6 | 1.4 | 40 |
| asthenia | 92 | 1.5 | 1.2 | 17 |
| diarrhoea | 142 | 1.4 | 1.2 | 14 |
| pyrexia | 74 | 1.3 | 1.1 | 6 |
| pneumonia | 68 | 1.3 | 1.0 | 5 |
| drug ineffective | 102 | 0.5 | 0.4 | 60 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.